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Introduction
Tumors must cope with an unpredictable microenvironment deplet-
ed of oxygen and nutrients but saturated in oxidative radicals, toxins, 
and immune-inflammatory mediators (1). This requires a process of 
adaptation, or “plasticity” (2), that improves tumor fitness via genet-
ic and nongenetic changes (3, 4), buffers stress signals (5), and repro-
grams metabolism for tailored bioenergetics needs (6).
A key decision in tumor adaptation is how best to allocate 
limited resources in the microenvironment (1) to either support 
cell proliferation, and therefore local tumor growth; or, converse-
ly, stimulate cell motility (7), thus enabling the dissemination 
of transformed cells to distant organs, or metastasis (8). Both 
responses are intensely energy-intensive, and it has been spec-
ulated that tumors can undergo dynamic cycles of each process, 
but not both at the same time in a mechanism called cell prolif-
eration-motility dichotomy (9), or phenotype-switching (10). 
Although this process may dictate metastatic competence and 
ultimately influence disease outcome, its mechanistic underpin-
nings (9) have remained elusive (11), with only a handful of regu-
lators of cell cycle transitions (12), transcriptional (13) and trans-
lational (14) programs, and membrane dynamics of cell motility 
(15) potentially implicated in phenotype switching (16).
In this context, a role for metabolic reprogramming in phe-
notype switching has not been widely investigated. We know that 
most tumors adopt a mostly glycolytic metabolism, the so-called 
Warburg effect (6), but recent evidence has reinforced a central 
role of mitochondrial biology as a driver of cancer traits (17, 18), 
in particular metastatic competence (19), even under microenvi-
ronment stress (20). Several mechanisms have been implicated in 
this process, including modulation of oxidative stress (21); cycles 
of organelle fusion and fission, i.e. dynamics (22); and horizon-
tal transfer of respiration-competent mitochondria from stromal 
cells (23, 24). Recently, an additional mechanism of active mito-
chondrial trafficking to the cortical cytoskeleton has been linked 
to greater tumor cell invasion and metastasis (25, 26), potential-
ly by providing a concentrated, “regional” energy source to fuel 
membrane dynamics of chemotaxis and tumor cell movements. 
Unexpectedly, a key regulator of this pathway was identified as 
syntaphilin (SNPH), a cytoskeletal protein known in neurons 
for arresting mitochondrial movement at sites of high energy 
demands (27, 28). Instead, SNPH was found to be expressed in 
cancer, but downregulated in advanced disease settings, blocking 
mitochondrial trafficking to the cortical cytoskeleton and sup-
pressing cell motility and invasion (29).
In this study, we explored the complexity of the SNPH pathway 
(29) as a potential regulator of proliferation-motility decisions in 
tumors (7). We identified an alternatively spliced isoform of SNPH 
that localizes to mitochondria of tumor cells and orchestrates bio-
energetics, buffering of ROS, and differential modulation of tumor 
cell proliferation versus cell invasion and dissemination, in vivo.
Tumors adapt to an unfavorable microenvironment by controlling the balance between cell proliferation and cell motility, but 
the regulators of this process are largely unknown. Here, we show that an alternatively spliced isoform of syntaphilin (SNPH), 
a cytoskeletal regulator of mitochondrial movements in neurons, is directed to mitochondria of tumor cells. Mitochondrial 
SNPH buffers oxidative stress and maintains complex II–dependent bioenergetics, sustaining local tumor growth while 
restricting mitochondrial redistribution to the cortical cytoskeleton and tumor cell motility. Conversely, introduction of 
stress stimuli to the microenvironment, including hypoxia, acutely lowered SNPH levels, resulting in bioenergetics defects 
and increased superoxide production. In turn, this suppressed tumor cell proliferation but increased tumor cell invasion via 
greater mitochondrial trafficking to the cortical cytoskeleton. Loss of SNPH or expression of an SNPH mutant lacking the 
mitochondrial localization sequence resulted in increased metastatic dissemination in xenograft or syngeneic tumor models 
in vivo. Accordingly, tumor cells that acquired the ability to metastasize in vivo constitutively downregulated SNPH and 
exhibited higher oxidative stress, reduced cell proliferation, and increased cell motility. Therefore, SNPH is a stress-regulated 
mitochondrial switch of the cell proliferation-motility balance in cancer, and its pathway may represent a therapeutic target.
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lines. L-SNPH was expressed in normal brain but mostly undetect-
able in all other tissues examined, including breast, colon, heart, 
kidney, liver, and lung, and present at a low level in the prostate 
(Figure 1C). Unexpectedly, S-SNPH was expressed at levels com-
parable to or higher than those of L-SNPH in the brain, and was 
present in other tissues, including heart, kidney, lung, and pros-
tate (Figure 1C). S-SNPH was also the dominant isoform in normal 
and tumor cell lines, whereas L-SNPH was present at a low level 
or undetectable (Figure 1D). Similar results were obtained with 
analysis of public databases, with broad expression of SNPH in all 
human tumors examined, albeit at different levels (Supplemental 
Figure 1A; supplemental material available online with this article; 
https://doi.org/10.1172/JCI93172DS1), as well as human cell lines 
representative of disparate tumor types (Supplemental Figure 1B).
Consistent with a predicted MLS (Figure 1B), S-SNPH (here-
after referred to as SNPH) was detected by Western blotting in 
both cytosol and mitochondria of prostate adenocarcinoma PC3 
cells (Figure 1E). Similarly, SNPH transfected in breast adeno-
Results
Identification of alternatively spliced SNPH isoforms. A genome-wide 
shRNA screen recently identified SNPH as a regulator of mito-
chondrial trafficking in tumors and potential metastasis suppres-
sor (29). Here, inspection of the human SNPH locus indicated the 
presence of at least two SNPH transcripts, potentially originated by 
alternative splicing of the 5′ end of the SNPH gene (Figure 1A). This 
process generated a previously unrecognized short SNPH isoform 
(S-SNPH) of 494 amino acids containing a mitochondrial localiza-
tion sequence (MLS) embedded in a new amino-terminal region 
(Figure 1, A and B). In contrast, a long SNPH isoform (L-SNPH) of 
538 amino acids corresponded to previously described “neuronal” 
SNPH (27, 28), containing an extra 44-amino-acid NH2-proline–rich 
region and no MLS (Figure 1, A and B). Downstream of the first 44 
residues, the two SNPH proteins were identical (Figure 1, A and B).
We next used gene expression assays that individually detect 
L-SNPH or S-SNPH (Figure 1A) to map the distribution and abso-
lute abundance of the two isoforms in human tissues and cell 
Figure 1. SNPH isoforms. (A) Schematic diagram of the human SNPH locus (based on the Vertebrate Genome Annotation [Vega] repository; http://
vega.archive.ensembl.org/index.html). The position and sequences of intron-exon boundaries, long (L) or short (S) SNPH transcripts, and TaqMan gene 
expression assays utilized for mRNA amplification of the two SNPH isoforms are indicated. (B) Schematic diagram of L-SNPH or S-SNPH protein isoforms. 
Pro, proline. (C and D) The indicated normal human tissues (C), normal diploid (MRC5) cells, or tumor cell types (D) were analyzed for L-SNPH or S-SNPH 
mRNA copy number, and normalized to 1,000 molecules of β-actin. Mean ± SEM (n = 3 per tissue or cell line examined). (E) PC3 cells were fractionated in 
cytosol (Cyto) or mitochondrial (Mito) extracts and analyzed by Western blotting. TCE, total cell extracts. (F) MCF-7 cells devoid of endogenous SNPH as in 
D were transfected with SNPH cDNA and analyzed by fluorescence microscopy. Merge image includes the F-actin channel (cyan). Scale bar: 5 μm. (G) PC3 
cells were fractionated in sub-mitochondrial extracts containing outer membrane (OM), inter-membrane space (IMS), inner membrane (IM), or matrix (M) 
and analyzed by Western blotting. The expression of SDHB, cytochrome c (Cyto c), or ClpP was used as a markers for each fraction. MTE, unfractionated 
mitochondrial extracts.
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2A). Conversely, shRNA-mediated loss of SNPH decreased oxygen 
consumption rates (OCR), a marker of oxidative metabolism (Figure 
2A), and reduced overall adenosine triphosphate (ATP) production in 
PC3 cells (Figure 2B). Glycolytic metabolism was also affected, with 
a modest, but significant, decrease in glucose consumption (Supple-
mental Figure 2B) and lactate production (Supplemental Figure 2C) 
after shRNA-SNPH knockdown. To validate these results, we next 
carried out reconstitution experiments in which SNPH- depleted PC3 
cells were transduced with adenovirus expressing SNPH (Ad-SNPH) 
(Supplemental Figure 2, D and E). Under these conditions, reexpres-
sion of SNPH restored OCR (Figure 2C) and ATP production (Fig-
ure 2D), whereas Ad-LacZ (Supplemental Figure 2, D and E) had no 
effect (Figure 2, C and D).
To further characterize the role of SNPH in mitochondrial 
metabolism, we next looked at the activity of individual oxidative 
phosphorylation complexes. Stable depletion of SNPH in PC3 cells 
reduced the activity of mitochondrial complex II (Figure 2, E and 
F), but not complex I (Figure 2, G and H), compared with control 
transfectants. This was associated with decreased expression of 
carcinoma MCF-7 cells, which are devoid of endogenous SNPH 
(Figure 1D; see complete unedited blots in the supplemental 
material.), localized to mitochondria, by fluorescence microsco-
py (Figure 1F). In terms of submitochondrial distribution, endog-
enous SNPH localized to both the inner and outer mitochondrial 
membranes of tumor cells, whereas matrix and inter-membrane 
space were unreactive (Figure 1G).
Mitochondrial SNPH regulates bioenergetics. To probe the function 
of SNPH in mitochondria, we next used multiple independent siRNA 
sequences that silence the expression of SNPH mRNA (Supplemen-
tal Figure 1C) and protein (Supplemental Figure 1D) in tumor and 
normal cell types. As an additional, alternative approach, we gener-
ated two independent clones of PC3 cells with stable knockdown of 
SNPH by short hairpin RNA (shRNA) (Supplemental Figure 1E). As 
cellular models for the targeting experiments, we focused on PC3 
and glioblastoma LN229 cells, representative of neuroendocrine and 
CNS origin, respectively, with high endogenous SNPH expression 
(Figure 1D). SNPH siRNA silencing did not affect total mitochondri-
al mass, compared with control transfectants (Supplemental Figure 
Figure 2. SNPH regulation of mitochondrial bioenergetics. (A and B) PC3 cells stably transduced with control pLKO or shRNA-SNPH (clone 0 or 5) were 
analyzed for OCR (A) or ATP production (B). Data are expressed as mean ± SD of replicates of a representative experiment (n = 3). ***P < 0.0001, by 
2-tailed Student’s t test (A). ***P < 0.001 by ANOVA and Bonferroni’s post-test (B). (C and D) PC3 cells transfected with control siRNA (Ctrl) or si RNA- 
SNPH were transduced with control adenovirus (Ad-LacZ) or SNPH-directed adenovirus (Ad-SNPH), and analyzed for OCR (C) or ATP production (D). Data 
are expressed as mean ± SD of replicates of a representative experiment (n = 3). ***P < 0.001 by ANOVA and Bonferroni’s post-test. (E and F) PC3 cells 
transduced with pLKO or shRNA-SNPH were analyzed for oxidative phosphorylation complex II (C.II) activity (E) and normalized to citrate synthase activity 
(F). Gray tracing, blank reaction. Data are expressed as mean ± SD of replicates of a representative experiment (n = 3). **P < 0.01 by ANOVA and Bonfer-
roni’s post-test. (G and H) The experimental conditions were as in E and F, except that transduced PC3 cells were analyzed for oxidative phosphorylation 
complex I (C.I) activity (G) and normalized to citrate synthase activity (H). Gray tracing, blank reaction. Data are expressed as mean ± SD of replicates of a 
representative experiment (n = 3). NS, not significant (P > 0.05) by ANOVA and Bonferroni’s post-test. (I) PC3 cells transduced with pLKO or shRNA-SNPH 
were treated with CHX, and aliquots of cell extracts harvested at the indicated time intervals after release (h) were analyzed by Western blotting. (J and 
K) Protein bands from the experiment in I were quantified by densitometric scanning after CHX release. Changes in SDHA (J) or SDHB (K) protein bands in 
pLKO or shRNA-SNPH are shown. Data are expressed as mean ± SD (n = 4). The statistical analyses are as follows: SDHA (J), 2 hours, P = 0.05; 4 hours,  
P < 0.0001; 6 hours, P = 0.0001; 8 hours, P = 0.0001; 10 hours, P < 0.0001; SDHB (K), 2 hours, P = 0.14; 4 hours, P = 0.0007; 6 hours,  
P < 0.0001; 8 hours, P < 0.0001; 10 hours, P < 0.0001, by 2-tailed Student’s t test.
Downloaded from http://www.jci.org on October 18, 2017.   https://doi.org/10.1172/JCI93172
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 7 5 8 jci.org   Volume 127   Number 10   October 2017
oxidative stress, including hyperoxidation of peroxiredoxin 3 (Prx3) 
(Supplemental Figure 3B), and increased NAD+/NADH ratio (Fig-
ure 3C) were also elevated in these settings. In rescue experiments, 
transfection of shRNA-SNPH–depleted cells with cDNA encoding 
the antioxidant SOD2 or Prx3 (Supplemental Figure 3B) reversed 
the increase in total cellular ROS (Figure 3A), as well as mitochon-
drial superoxide production (Supplemental Figure 3C).
Based on these observations, we next asked whether oxidative 
damage affected the stability and/or function of mitochondrial 
oxidative phosphorylation complex subunits. Consistent with this 
possibility, treatment of PC3 cells with the oxidative stress stimulus 
2,3-dimethoxy-1,4-naphthoquinone (DMNQ) resulted in a concen-
tration-dependent decrease in SDHA and SDHB expression (Figure 
3D and Supplemental Figure 3D). Consistent with oxidative dam-
age, this was associated with Prx3 hyperoxidation and potent induc-
tion of the oxidative stress–regulated, cytoprotective transcription 
factor Nrf2 (30) in treated cells (Figure 3D and Supplemental Fig-
ure 3D). Similar results were obtained after exposure of PC3 cells 
the complex II subunits succinate dehydrogenase A (SDHA) and 
B (SDHB) (Supplemental Figure 2F), whereas SDHC or complex 
III or complex V subunits were not affected (Supplemental Figure 
2F and Supplemental Figure 1E). Consistent with these findings, 
shRNA-SNPH knockdown resulted in accelerated degradation 
of SDHA and SDHB (Figure 2I), and significantly shortened the 
half-life of both proteins, as quantified in cycloheximide (CHX) 
block experiments (Figure 2, J and K). Other subunits of oxida-
tive phosphorylation complexes, including ATP5A (complex V) 
and UQCRC2 (complex III), were not affected (Figure 2I), and the 
half-life of COX-IV (complex IV) was unchanged with or without 
SNPH knockdown (Supplemental Figure 2G).
Mitochondrial SNPH regulation of oxidative stress. Consistent 
with defective mitochondrial bioenergetics, shRNA-SNPH knock-
down in PC3 cells resulted in increased production of total ROS 
(Figure 3A). Specifically, loss of SNPH was associated with height-
ened generation of mitochondria-derived superoxide, compared 
with control transfectants (Figure 3B). Known cellular markers of 
Figure 3. Effect of SNPH on mitochondrial oxidative stress. (A) LN229 cells expressing control siRNA (Ctrl) or siRNA-SNPH were transfected with cDNA 
encoding antioxidant SOD2 or Prx3 and analyzed for total ROS production by fluorescence microscopy. Data are expressed as mean ± SD of single-cell 
determinations (Ctrl, n = 109; SNPH, n = 75; SOD2, n = 74; and Prx3, n = 55). **P < 0.01 by ANOVA and Bonferroni’s post-test. CellROX, ROS sensor. (B) PC3 
cells transduced with pLKO or shRNA-SNPH (clones 0 and 5) were analyzed for mitochondrial superoxide production (mitoSOX) by fluorescence micro-
scopy. Data are expressed as mean ± SD of single cell determinations (pLKO, n = 202; SNPH #0, n = 296; SNPH #5, n = 297). ***P < 0.001 by ANOVA and 
Bonferroni’s post-test. FU, fluorescence units. (C) PC3 shRNA-SNPH #0 cells were analyzed for NAD+/NADH ratio. Data are expressed as mean ± SD of 
replicates of a representative experiment (n = 3). **P = 0.001, by 2-tailed Student’s t test. (D–F) PC3 cells were treated with the indicated increasing con-
centrations of the oxidative stimuli DMNQ (D), H2O2 (E), and paraquat (PQ, F) and analyzed by Western blotting. Bottom panels (E and F): Densitometric 
quantification of SDHA, SDHB, or Prx-SO3 protein bands. Data are expressed as mean ± SD (n = 3). *P < 0.05; **P < 0.01; by ANOVA and Bonferroni’s post-
test. (G) PC3 shRNA-SNPH #0 cells were treated with the mitochondrial superoxide scavenger MT and incubated with CHX, and cell extracts harvested 
at the indicated time intervals after release (h) were analyzed by Western blotting. (H) Densitometric quantification of SDHA, SDHB, or COX-IV proteins 
bands from the experiment in G. Data are expressed as mean ± SD (n = 4). The statistical analyses are as follows: SDHA, 2 hours, NS; 4 hours, P = 0.001; 6 
hours, NS; 8 hours, NS; 10 hours, P = 0.033; SDHB, NS for all time points; COX-IV, NS for all time points by 2-tailed Student’s t test.
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increased chemotaxis associated with SNPH depletion (Supplemen-
tal Figure 4C), reducing the speed of cell movements (Supplemental 
Figure 4D) and the distance traveled by individual cells (Supple-
mental Figure 4E). Similar results were obtained with an indepen-
dent experimental approach, where transfection of SNPH-deplet-
ed LN229 cells with antioxidant SOD2 or Prx3 also reversed the 
increased chemotaxis induced by SNPH loss (Figure 4C), with com-
parable inhibition of the speed of cell migration (Figure 4D) and dis-
tance traveled per cell (Figure 4E) to the levels of control cultures.
Mitochondrial SNPH differentially regulates tumor cell prolifera-
tion. In addition to increased cell motility (Figure 4C and Supple-
mental Figure 4D), SNPH depletion blocked tumor cell proliferation 
(Figure 5A, top) without loss of cell viability (Figure 5A, bottom). 
Importantly, tumor cells lacking endogenous SNPH, including 
C4-2B or breast adenocarcinoma MCF-7 cells (Supplemental Fig-
ure 5A), were not affected (red boxes in Figure 5A, top). Consistent 
with these data, loss of SNPH also suppressed colony formation in 
semisolid medium (Figure 5, B and C). In reciprocal experiments, 
forced expression of SNPH was sufficient to increase tumor cell 
proliferation, compared with control transfection (Figure 5D). The 
requirement(s) of SNPH regulation of tumor cell proliferation was 
next investigated. SNPH depletion did not appreciably affect BrdU 
incorporation (Supplemental Figure 5B), a measure of S-phase, 
but significantly increased the percentage of cells with G2/M DNA 
content (Supplemental Figure 5C), suggestive of mitotic arrest. 
Consistent with this possibility, SNPH depletion was associated 
with increased levels of mitotic cyclin B1, whereas the expression 
to hydrogen peroxide (Figure 3E) or paraquat (Figure 3F), a redox 
cycler that stimulates superoxide production, resulting in concen-
tration-dependent loss of SDHB and, to a lesser extent, SDHA 
expression (Figure 3, E and F). Conversely, selective scavenging 
of mitochondrial superoxide with MitoTempo (MT) inhibited 
the increase in mitochondrial ROS induced by SNPH knockdown 
(Supplemental Figure 3F), and restored SDHA and SDHB levels in 
these settings (Figure 3G). Accordingly, MT treatment normalized 
the half-life of both complex II subunits, SDHA and SDHB, in CHX 
block experiments (Figure 3, G and H), whereas the half-life of 
COX-IV was unchanged with or without MT (Figure 3H).
SNPH regulation of oxidative stress controls mitochondrial traf-
ficking and tumor cell motility. Next, we asked whether SNPH reg-
ulation of mitochondrial oxidative stress was important for tumor 
behavior. For these experiments, we used the model of LN229 
glioblastoma cells, recently utilized to characterize the SNPH 
pathway in tumors (29), as well as prostate adenocarcinoma C4-2B 
cells, which have undetectable levels of endogenous SNPH (Fig-
ure 1D). Using these cellular models, forced expression of SNPH 
was sufficient to suppress mitochondrial trafficking to the cortical 
cytoskeleton (Figure 4A and Supplemental Figure 4A), which fuels 
membrane dynamics of chemotaxis and cell invasion (29).
Mechanistically, treatment of SNPH-depleted LN229 cells with 
MT, alone or in combination with the ROS scavenger N-acetyl-cyste-
ine (NAC) suppressed mitochondrial trafficking to the cortical cyto-
skeleton (Figure 4B and Supplemental Figure 4, B and C). In turn, 
MT treatment, with or without NAC, was sufficient to suppress the 
Figure 4. SNPH regulation of mitochondrial oxidative stress controls tumor cell motility. (A) LN229 cells were transfected with vector or Flag-SNPH cDNA 
and analyzed for subcellular mitochondrial localization by confocal fluorescence microscopy. Three-dimensional isosurface renderings of representative cells 
are shown. (B) LN229 cells transfected with control siRNA or siRNA-SNPH were treated with vehicle or MT (200 μM) and analyzed by fluorescence microscopy. 
Masks are superimposed to the mitochondrial fluorescence channel (MTC02) to indicate the cell border (cyan lines, based on the actin channel) and the cortical 
region (area between the cyan and magenta lines). Arrowheads, cortical mitochondria. Scale bar: 10 μm. (C–E) LN229 cells transfected with siRNA-SNPH were 
transfected with vector, SOD2, or Prx3 cDNA and analyzed for cell motility in a 2D chemotaxis chamber (C), with quantification of speed of cell migration (D) 
and distance traveled by individual cells (E). Each tracing in C and symbol in E corresponds to an individual cell. Data are expressed as mean ± SEM (n = 91–112). 
***P < 0.0001, by ANOVA and Bonferroni’s post-test. The cutoff velocities for each condition in 2D chemotaxis experiments (C) are indicated.
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of cyclin A or cyclin D1 was unchanged (Supplemental Figure 5D). 
Mechanistically, transfection of SNPH-depleted cells with antioxi-
dant SOD2 cDNA restored tumor cell proliferation (Figure 5E) and 
reversed the cell cycle arrest at G2/M (Figure 5F), compared with 
control transfection.
Mitochondrial SNPH modulates cell proliferation–cell motility 
decisions in cancer. Next, we asked whether the mitochondrial 
localization of this SNPH isoform was required for tumor func-
tions. Reconstitution of shRNA-SNPH–silenced PC3 cells with 
full-length (FL) SNPH (Supplemental Figure 6A) reversed the 
bioenergetics defects in oxygen consumption (Figure 6A) and 
ATP production (Figure 6B) associated with SNPH depletion. 
Conversely, reconstitution of these cells with a SNPH mutant 
lacking the MLS (Δ-MLS) was ineffective (Figure 6, A and B, 
and Supplemental Figure 6A). In these studies, FL SNPH and 
Δ-MLS SNPH were expressed at comparable levels in reconsti-
tuted PC3 cells (Supplemental Figure 6A). Next, we examined 
the requirement of mitochondrial localization in SNPH regula-
tion of mitochondrial movement and cell motility-proliferation. 
Consistent with the data above, forced expression of FL SNPH 
in C4-2B cells (Supplemental Figure 6B) inhibited mitochondrial 
trafficking to the cortical cytoskeleton (Figure 6C) and promoted 
increased cell proliferation (Figure 6D), compared with control 
transfection. Conversely, expression of Δ-MLS SNPH in C4-2B 
cells (Supplemental Figure 6B) was considerably less effec-
tive, partially reducing mitochondrial trafficking (Figure 6C) 
and modestly increasing cell proliferation (Figure 6D). Similar 
results were obtained in LN229 cells, where FL SNPH inhibited 
mitochondrial trafficking (Supplemental Figure 6C) and promot-
ed cell proliferation (Supplemental Figure 6D), whereas Δ-MLS 
SNPH had a limited effect (Supplemental Figure 6, C and D). 
Finally, reconstitution of shRNA-SNPH–depleted PC3 cells with 
FL SNPH abolished the increase in tumor cell invasion induced 
by SNPH loss, whereas Δ-MLS SNPH had no effect (Figure 6E 
and Supplemental Figure 6E).
Based on these observations, we next asked whether the 
localization of SNPH to mitochondria was required to modu-
late tumor cell dissemination in vivo. For these experiments, we 
utilized the mCherry-labeled Yumm1.7 cell line, derived from a 
genetically engineered mouse model of invasive melanoma car-
rying the genotype BrafV600E; Cdkn2a–/–;Pten–/– (31) and utilized 
in recent studies (32). For these experiments, Yumm1.7 cells 
expressing negligible levels of endogenous SNPH (Supplemen-
tal Figure 6F) were stably transfected with vector or SNPH vari-
ants and first analyzed for cell motility/proliferation responses 
in culture. Transfection of FL SNPH suppressed Yumm1.7 cell 
invasion across Matrigel, compared with vector control transfec-
tion (Supplemental Figure 6G) and in agreement with the data 
above. In contrast, expression of Δ-MLS SNPH had no effect in 
Yumm1.7 cells (Supplemental Figure 6G). In these experiments, 
expression of FL SNPH or Δ-MLS SNPH did not significantly 
modulate proliferation of Yumm1.7 cells (Supplemental Figure 
6H). When reconstituted subcutaneously in syngeneic C57BL/6 
mice, Yumm1.7 cells expressing vector disseminated to the lung, 
as quantified by immunocytochemistry of mCherry reactivity 
(Figure 6, F and G), and in agreement with recent observations 
(32). Under these conditions, expression of FL SNPH abolished 
metastatic seeding of Yumm1.7 cells to the lungs, whereas trans-
fection of Δ-MLS SNPH was associated with increased tumor cell 
dissemination in vivo (Figure 6, F and G).
Figure 5. Mitochondrial SNPH supports tumor cell proliferation. (A) The indicated tumor cells transfected with control siRNA (Ctrl) or siRNA-SNPH were 
analyzed by direct cell counting (top) or cell viability by trypan blue exclusion (bottom) after 72 hours. The same number of cells were seeded at time 0. 
Data are expressed as mean ± SEM (n = 4). Red boxes indicate two cell types (C4-2B and MCF-7) with low to undetectable levels of endogenous SNPH. The 
statistical analyses per each cell type are as follows: BPH1, P = 0.03; A549, P = 0.004; H1299, NS; C4-2B, NS; DU145, P = 0.03; PC3, P = 0.002; LN229, P = 
0.002; U251, P < 0.0001; U87, P = 0.03; MCF-7, NS; MDA-231, P = 0.01; Hs578T, P = 0.02 by 2-tailed Student’s t test. (B and C) PC3 cells transduced with pLKO 
or shRNA-SNPH (clones 0 and 5) were analyzed in a colony formation assay, and crystal violet–stained colonies (B) were counted after 10 days (C). Data are 
expressed as mean ± SEM (n = 3). ***P < 0.001 by ANOVA and Bonferroni’s post-test. (D) The indicated tumor cell types were transfected with vector or 
SNPH cDNA and analyzed by direct cell counting after 72 hours. Data are expressed as mean ± SD (n = 3). ***P < 0.0001, by 2-tailed Student’s t test. (E) PC3 
cells transduced with pLKO or shRNA-SNPH were transfected with SOD2 cDNA and analyzed by direct cell counting. Data are expressed as mean ± SD (n = 3). 
*P < 0.01, by ANOVA and Bonferroni’s post test. (F) PC3 cells transduced with shRNA-SNPH were reconstituted with vector or SOD2 cDNA and analyzed by 
propidium iodide staining and flow cytometry. The cellular fractions in the indicated cell cycle phases are indicated. Data are expressed as mean ± SD (n = 3). 
**P = 0.01 by 2-tailed Student’s t test.
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Reciprocal regulation of tumor growth and metastasis by SNPH. 
We next carried out a reciprocal experiment in vivo and analyzed 
the xenograft growth of PC3 cells stably transduced with two inde-
pendent shRNA-SNPHs in immunocompromised mice. In these 
experiments, stable depletion of SNPH suppressed the growth 
of superficial PC3 xenograft tumors, compared with pLKO trans-
fection (Figure 7A). To further investigate the role of this pathway 
in metastasis, we isolated pLKO-transfected cells that had spon-
taneously metastasized to the lung or liver of engrafted animals. 
These lung or liver metastatic cell lines showed constitutive down-
regulation of SNPH (Figure 7B) and markers of oxidative stress, 
including greater mitochondrial superoxide production (Figure 
7C) and Prx hyperoxidation and reduced SOD2 levels (Figure 7D). 
In line with these findings, analysis of public databases revealed 
that metastatic breast cancer (Supplemental Figure 7A) or meta-
static prostate cancer (Supplemental Figure 7B) had reduced levels 
of SNPH compared with the corresponding primary tumor. Phe-
nocopying the effect of SNPH silencing, loss of endogenous SNPH 
in metastatic tumor cells was associated with decreased expres-
sion of the complex II subunits SDHA and SDHB (Figure 7D and 
Supplemental Figure 7C), diminished complex II activity (Figure 
7E and Supplemental Figure 7D), and lower OCR (Supplemental 
Figure 7E), compared with parental, pLKO transfection.
When analyzed for changes in the cell proliferation-motility bal-
ance, lung or liver metastatic cells showed reduced colony formation 
(Figure 7, F and G) but increased 2D chemotaxis (Figure 7H), charac-
terized by greater speed of cell migration (Figure 7I) and longer dis-
tance traveled by individual cells (Supplemental Figure 7F). Finally, 
these metastatic cells expressed markers of epithelial-mesenchymal 
transition (EMT), including β-catenin, Slug, and vimentin (Figure 
7J), whereas ZO1 modulation was observed in lung but not liver met-
astatic cells, and claudin 1 expression was unchanged (Figure 7J).
Stress-regulated exploitation of the SNPH pathway in cancer. 
Next, we asked whether stress conditions of the tumor microenvi-
ronment affected SNPH levels in tumors. Exposure of PC3 cells to 
hypoxia (1% O2 for 24 hours) acutely downregulated SNPH levels 
(Figure 8A) as early as 3 hours after treatment (Supplemental Fig-
ure 8A), and was associated with Prx hyperoxidation and HIF1α 
stabilization (Figure 8A). Similar findings were observed in cases 
of clear cell renal cell carcinoma in vivo, where HIF1α stabilization 
due to mutations or deletions in its negative regulator von Hip-
pel–Lindau (VHL) (33) (Figure 8B) or decreased VHL copy number 
(Supplemental Figure 8B) correlated with reduced levels of SNPH. 
Functionally, loss of SNPH in hypoxic cells was associated with 
increased mitochondrial trafficking to the cortical cytoskeleton 
(Figure 8, C and D) and greater tumor cell motility, as determined 
in a wound closure assay (Supplemental Figure 8, C and D). Oxi-
dative stress generated by DMNQ treatment also lowered SNPH 
protein (Figure 8E) and mRNA (Figure 8F) expression in PC3 cells.
Finally, we asked whether the SNPH pathway was selectively 
exploited in cancer, compared with normal cells. Silencing of SNPH in 
primary human HFFs or normal prostate epithelial RWPE1 cells had 
marginal effects on cellular bioenergetics, with a modest decrease in 
OCR (Figure 8G) and ATP production (Figure 8H). Similarly, SNPH 
silencing in HFF cultures did not generate oxidative stress, with no 
Prx3 hyperoxidation observed in these settings (Supplemental Fig-
ure 8E). Finally, depletion of SNPH in either HFFs or RWPE1 cells 
did not affect 2D chemotaxis (Figure 8I), with no changes observed 
in the speed of cell migration (Figure 8J) or distance traveled per cell 
(Figure 8K), compared with control transfectants.
Figure 6. Mitochondrial SNPH regulation of metastasis. (A and B) siRNA-SNPH PC3 cells were reconstituted with vector (pCMV), FL SNPH, or an SNPH 
mutant deleted in the MLS (Δ-MLS), and analyzed for OCR (A) or ATP production (B). Data are mean ± SD (n = 3). **P < 0.01; ***P < 0.001 by ANOVA and 
Bonferroni’s post-test. (C and D) C4-2B cells were transfected with pCMV6, FL SNPH, or Δ-MLS SNPH and analyzed for mitochondrial trafficking to the cor-
tical cytoskeleton (C) or direct cell counting (D). For C, data are mean ± SEM (vector, n = 89; FL SNPH, n = 96; Δ-MLS SNPH, n = 87). **P < 0.01; ***P < 0.001 
by ANOVA and Bonferroni’s post-test. For D, data are mean ± SD (n = 6). (E) shRNA-SNPH PC3 cells were reconstituted with pCMV6, FL SNPH, or Δ-MLS 
SNPH and analyzed for Matrigel invasion. Data are mean ± SEM (n = 3). ***P < 0.001, by ANOVA and Bonferroni’s post-test. (F) Yumm1.7 cells expressing 
mCherry and stably transfected with pCMV6, FL SNPH, or Δ-MLS SNPH were injected subcutaneously into syngeneic C57BL/6 mice, and mCherry-positive 
cells (insets) disseminated to the lungs were detected by immunocytochemistry. Scale bar: 50 μm. (G) Quantification of mCherry-positive Yumm1.7 cells 
transfected as in F in lungs of reconstituted animals. Each symbol corresponds to the mean number of disseminated cells per lung of an individual animal. 
DTC, disseminated tumor cells. *P < 0.05; ***P < 0.001, by ANOVA and Bonferroni’s post-test.
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SNPH mutant lacking the MLS dramatically increased metastatic 
dissemination in syngeneic as well as xenograft tumor models in 
vivo. Accordingly, tumor cell lines established from lung or liver 
metastatic sites in vivo exhibited lower levels of SNPH compared 
with their primary sites, higher oxidative stress, reduced cell pro-
liferation, and heightened cell motility.
Previously considered “neuron-specific” (27), SNPH has been 
known as a negative regulator of mitochondrial trafficking, teth-
ering mitochondria to cytoskeletal microtubules and halting their 
movements at axonal regions with high energy demands (28). 
Unexpectedly, a similar pathway was recently uncovered in cancer 
(29), where SNPH prevented the repositioning of mitochondria to 
the cortical cytoskeleton, a process that fuels chemotaxis and cell 
invasion (25, 26), thus suppressing tumor cell movements (29). 
Here, we uncovered a mechanistic underpinning of the SNPH 
pathway in cancer, centered on the expression of a previously 
unrecognized, alternatively spliced SNPH isoform, characterized 
Discussion
In this study, we have identified an alternatively spliced isoform 
of SNPH (27, 28) that localizes to mitochondria and functions as a 
stress-regulated switch for proliferation-motility decisions in can-
cer. High levels of SNPH maintain efficient, “non-leaky” mito-
chondrial bioenergetics, which sustains tumor cell proliferation 
while suppressing cell motility (Figure 9). Reciprocally, downreg-
ulation of SNPH due to oxidative or hypoxic stress impairs mito-
chondrial metabolism, shuts off cell proliferation and stimulates 
greater tumor cell motility and invasion (Figure 9). A critical sig-
naling regulator of this response was mitochondria-produced 
superoxide, which promoted oxidative degradation of the com-
plex II subunits SDHA and SDHB, cell cycle arrest at G2/M, and 
heightened mitochondrial trafficking to the cortical cytoskeleton 
to fuel membrane dynamics of cell motility (Figure 9). Altogether, 
this pathway functioned as a major switch to regulate the meta-
static propensity in vivo, as depletion of SNPH or expression of a 
Figure 7. SNPH regulation of cell proliferation-motility in vivo. (A) PC3 cells transduced with pLKO or shRNA-SNPH (clones 0 and 5) were injected 
subcutaneously in immunocompromised mice (5 mice per group; 2 tumors/mouse), and tumor volume was quantified with a caliper at the indicated 
time intervals. Each symbol corresponds to an individual tumor. On day 20, pLKO vs. SNPH #0, P < 0.001; pLKO vs. SNPH #5, P < 0.05, by ANOVA and 
Bonferroni’s post-test. (B) pLKO-transduced PC3 cells or pLKO-transduced PC3 cells isolated from a liver or lung metastatic site (Met) from the experiment 
in A were analyzed for SNPH mRNA levels by qPCR. Data are expressed as mean ± SD (n = 3). ***P < 0.001 by ANOVA and Bonferroni’s post-test. (C and 
D) The metastatic cell lines in B were analyzed for mitochondrial superoxide production by mitoSOX reactivity and fluorescence microscopy (C) or Western 
blotting (D). Data in C are expressed as mean ± SEM of single-cell determinations (n = 76–200). ***P < 0.001 by ANOVA and Bonferroni’s post-test. (E) 
The indicated metastatic cell lines were analyzed for mitochondrial oxidative phosphorylation complex II (C.II) activity at the indicated time intervals. (F 
and G) The indicated metastatic cell lines were analyzed in a colony formation assay (F), and crystal violet–stained colonies were quantified after 10 days 
(G). Data are expressed as mean ± SD (n = 3). **P < 0.01; ***P < 0.001 by ANOVA and Bonferroni’s post-test. (H and I) The indicated metastatic cell lines 
were analyzed for cell motility in a 2D chemotaxis chamber (H) with quantification of speed of cell migration (I). Data are expressed as mean ± SEM (n = 
104–106). ***P < 0.0001, by ANOVA and Bonferroni’s post-test. (J) The indicated metastatic cell lines were analyzed by Western blotting.
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observations). Together, these data suggest the possibility of a dif-
ferential spatial organization for the diverse SNPH functions in 
mitochondria, where outer membrane–associated SNPH provides 
organelle attachment to the cytoskeleton (27, 29), whereas inner 
membrane SNPH sustains efficient, non-leaky oxidative metabo-
lism. Mechanistic data presented reinforce the absolute require-
ment of mitochondrial localization for SNPH function in tumors, 
as an SNPH Δ-MLS mutant lacked the ability to affect oxidative 
bioenergetics, mitochondrial trafficking to the cortical cytoskele-
ton, and cell proliferation.
Consistent with this view, mitochondrial SNPH emerged here 
as a regulator of organelle bioenergetics, preserving the stability 
and function of the complex II subunits SDHA and SDHB against 
oxidative damage. Although the structural arrangement of com-
plex II is known (34), how subunit integrity is preserved, especially 
during oxidative (35) or proteotoxic (36) stress, has not been clear-
ly delineated. We know that pharmacologic or genetic targeting of 
complex II causes electron leakage (37) and increased superoxide 
production (38). Here, we identified mitochondrial superoxide as 
a potent stimulus for SDHA and SDHB degradation, potentially 
via protein oxidation, further impairing energy production under 
by a unique mitochondrial localization. At variance with a canoni-
cal, long SNPH isoform, which corresponds to previously described 
“neuronal” SNPH (27), the new, short SNPH isoform was broad-
ly expressed, albeit at wide-ranging levels, in both neuronal and 
non-neuronal tissues, including primary human tissues and tumor 
cell lines. A detailed molecular understanding of how the SNPH 
gene is differentially processed, including the potential generation 
of additional isoform(s) from this locus, remains to be elucidated. 
However, it is intriguing that analysis of public databases points to 
a potential role of stress-regulated transcriptional mechanisms in 
SNPH gene expression, in keeping with the stress-regulated mod-
ulation of SNPH levels observed here in tumor cells.
Consistent with its predicted mitochondrial localization, the 
new, short SNPH isoform accumulated in mitochondria of tumor 
cells, sorting to both the inner and outer organelle membranes. It 
seems plausible that the putative transmembrane (TM) domain 
embedded in the COOH-terminus of SNPH (27) provides mem-
brane insertion at both mitochondrial locations, and, consistent 
with this possibility, deletion of the TM domain disrupted mito-
chondrial tethering to cytoskeletal microtubules (27) and impaired 
mitochondrial support of tumor cell proliferation (our unpublished 
Figure 8. Hypoxic and oxidative stress regulation of SNPH. (A) PC3 cells were exposed to normoxia (N) or hypoxia (H; 1% O2 for 24 hours) and analyzed by 
Western blotting. (B) Cases of clear cell renal cell carcinoma in the TCGA database were stratified for SNPH mRNA expression and VHL mutational status. 
Mut, mutations; Trunc, truncated; del, deletions. Each symbol corresponds to an individual tumor. **P < 0.01; ***P < 0.001 by ANOVA and Bonferroni’s 
post-test. (C and D) LN229 cells exposed to normoxia or hypoxia as in A were analyzed for mitochondrial trafficking to the cortical cytoskeleton by fluo-
rescence microscopy (C), and cortical mitochondria (mito) were quantified (D). Each symbol corresponds to an individual cell. ***P < 0.0001, by 2-tailed 
Student’s t test. The representative images displayed in C are brightness- and contrast-enhanced to highlight cortical mitochondria. Quantification was 
done in unsaturated images. (E and F) PC3 cells were treated with the indicated concentrations of DMNQ and analyzed by Western blotting (E) or qPCR 
amplification of SNPH mRNA (F). Data are expressed as mean ± SD (n = 3). ***P < 0.001, by ANOVA and Bonferroni’s post-test. (G and H) Normal diploid 
HFFs or normal human prostate epithelial cells (RWPE1) were transfected with control siRNA or siRNA-SNPH and analyzed for OCR (G) or ATP production 
(H). Data are mean ± SD (HFFs, n = 3; RWPE1, n = 12). *P = 0.001 to P < 0.0001; NS, not significant, by 2-tailed Student’s t test. (I) HFFs (top) or RWPE1 
cells (bottom) transfected as in G were analyzed for cell motility in a 2D chemotaxis chamber. Each trace corresponds to the movements of an individual 
cell. (J and K) HFFs or RWPE1 cells transfected as in G were analyzed by 2D chemotaxis, and speed of cell migration (J) and distance traveled by individual 
cells (G) were quantified. Data are expressed as mean ± SD (HFFs, n = 35–42; RWPE1 cells, n = 50–52). NS, 2-tailed Student’s t test.
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In terms of disease relevance, we have shown here that expres-
sion of mitochondria-localized SNPH is sufficient to suppress tumor 
cell dissemination from xenograft tumors as well as in syngeneic 
models of early metastatic seeding in immunocompetent animals, 
defining this pathway as a conceptually novel metastasis suppressor. 
Conversely, we found that SNPH becomes transcriptionally down-
regulated in cells that have acquired the ability to metastasize in 
vivo, correlating with a cellular phenotype of heightened oxida-
tive stress, reduced cell proliferation, and increased cell motility. 
The acquisition of metastatic competence reflects a complex and 
multifaceted transcriptional and posttranscriptional program (48), 
including modulation of intrinsic antioxidant mechanisms (45). 
How SNPH participates in this process remains to be fully eluci-
dated, but data collected from analysis of public databases and pri-
mary patient cohorts revealed that downregulation or loss of SNPH 
is a common feature of tumor progression, correlating with met-
astatic disease and worse outcome (29). Our data indicating that 
stress conditions of the tumor microenvironment, such as hypoxia 
and oxidative damage (1), acutely lower SNPH levels may explain 
the silencing of this pathway in advanced disease, coinciding with 
the emergence of a restrictive and unfavorable microenvironment, 
typically depleted of oxygen and nutrient (1).
Based on these findings, we propose a model in which SNPH 
functions as a stress-regulated mitochondrial “rheostat” for allo-
cation of often limited resources of the microenvironment in 
proliferation-motility decisions (9), or phenotype-switching (10). 
stress. How mitochondrial SNPH prevents superoxide-induced 
SDHA or SDHB oxidation and degradation remains to be eluci-
dated. One possibility is that SNPH operates in concert with other 
regulators of complex II (39), including survivin (26), to preserve 
subunit assembly and optimal bioenergetics, especially under 
stress conditions. In fact, it is intriguing that compared with other 
mitochondrial respiration complexes, complex II appears especial-
ly vulnerable to stress stimuli, including defective mitochondrial 
protein folding (40–42) and oxidative damage (the present study).
Although it has long been known that tumors produce more 
mitochondrial superoxide than normal tissues, a role of this 
pathway in disease progression is controversial, and likely con-
text dependent (43). Low levels of ROS may contribute to tumor-
igenesis via increased DNA damage and activation of oncogene 
signaling (44), whereas higher generation of ROS may trigger 
cytotoxicity and suppress metastasis (45). Here, the heightened 
production of mitochondrial superoxide in response to SNPH 
depletion triggered a dual phenotype of inhibition of tumor cell 
proliferation via G2/M arrest and stimulation of cell motility by 
increasing mitochondrial trafficking to the cortical cytoskeleton 
(25). This is consistent with a long-held tenet that ROS mediate 
cell motility (46), contributing to the acquisition of an EMT phe-
notype (47) and metastatic competence (21). Conversely, a role 
for ROS signaling in subcellular mitochondrial trafficking and a 
pathway of “regional” bioenergetics of cell motility (25) have not 
been previously described.
Figure 9. A mitochondrial SNPH “rheostat” for cell proliferation-motility decisions in cancer. An adequate supply of oxygen and nutrients in the tumor 
microenvironment maintains high levels of SNPH in mitochondria for efficient, “non-leaky” oxidative bioenergetics and low ROS generation. These con-
ditions support continued tumor cell proliferation while halting mitochondrial trafficking to the cortical cytoskeleton as a “regional” energy source to fuel 
membrane dynamics of cell motility and invasion. Conversely, the emergence of an oxidative and hypoxic microenvironment, typical of advanced tumors, 
acutely lowers SNPH levels, compromising oxidative phosphorylation complex II integrity and mitochondrial bioenergetics. The resulting increase in ROS 
inhibits tumor cell proliferation, while promoting increased mitochondrial trafficking to the cortical cytoskeleton and focal adhesion kinase–dependent 
(FAK-dependent) tumor cell migration and invasion. KIF5, kinesin family member 5; TRAK, trafficking kinesin-binding protein 1.
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Cell culture. Human glioblastoma (LN229, U251, and U87), 
prostate adenocarcinoma (LNCaP, C4-2B, DU145, and PC3), breast 
epithelial (MCF10A), breast adenocarcinoma (MCF7, Hs578T, and 
MDA-MB-231), lung adenocarcinoma (A549 and H1299), human 
diploid fibroblasts (MRC5), prostate epithelial cells (RWPE-1), and 
mouse fibroblasts (NIH 3T3) were obtained from ATCC, and main-
tained in culture according to the supplier’s specifications. Benign 
prostate hyperplasia (BPH1) cells were a gift from Simon Hayward 
(Vanderbilt University, Nashville, Tennessee, USA). A highly met-
astatic clone of PC3 cells colonizing the bone (PC3-ML) was a gift 
from Alessandro Fatatis (Drexel University College of Medicine, 
Philadelphia, Pennsylvania, USA). Primary HFFs were a gift from 
Meenhard Herlyn (Wistar Institute). Yumm1.7 cells were a gift from 
Marcus Bosenberg (Yale University, New Haven, Connecticut). 
Hypoxic treatment was carried out using an enclosed chamber (Bio-
Spherix) flushed with a nitrogen and CO2 gas. The O2 and CO2 con-
centrations in the chamber were maintained at 1% and 5%, respec-
tively, using an oxygen and carbon dioxide controller (BioSpherix). 
These conditions were maintained constant throughout the course 
of the experiments.
Plasmids, mutagenesis, and transfections. TrueORF pCMV6-Entry-
myc-Flag plasmids encoding the short isoform of SNPH (NM_014723, 
catalog RC207749), SOD2 (catalog RC202330), and Prx3 (catalog 
RC205080) were from Origene. The human ORF for the long iso-
form of SNPH from the Kazusa DNA Research Institute was obtained 
as HaloTag(R) in pFN21A (NM_001318234.1, Promega). Short SNPH 
mutants lacking the microtubule-binding domain (Δ-MTB, Δ86–159 
aa), TM domain (Δ-TM, Δ425–444 aa), or MLS (Δ-MLS, Δ1–20 aa) 
were generated using a Stratagene QuikChange II XL Site-Direct-
ed Mutagenesis Kit (Agilent Technologies) and confirmed by DNA 
sequencing. Cells were transfected with 2 μg pcDNA plus 4 μl X-treme 
gene HP (Roche) for 24 hours in complete medium, washed, and sub-
jected to the indicated treatments.
Adenoviral vectors expressing SNPH were produced using Gate-
way technology (Thermo Fisher Scientific). Briefly, SNPH or LacZ 
cDNA was inserted into pDONR221 vector and recombined into the 
adenovirus expression vector pAd/CMV/V5-DEST. The plasmids 
were digested with PacI restriction enzyme and transfected in 293A 
cells for production of adenoviruses. The cells containing adenovirus-
es were collected at 7 days after transfection, according to the manu-
facturer’s instructions.
Gene silencing. Gene knockdown experiments by siRNA were car-
ried out as described previously (20). The following sequences were 
used: control, ON-TARGETplus Non-targeting siRNA pool (Dharma-
con, D-001810), or human SNPH siRNA (Dharmacon, L-020417, or 
Santa Cruz Biotechnology Inc., sc-41369). Tumor cells were transfect-
ed with the individual siRNA pools at 30 nM in Lipofectamine RNAi-
MAX (Invitrogen) at a 1:1 ratio (vol siRNA 20 μM/vol Lipofectamine 
RNAiMAX). After 48 hours, the various transfected cells were validat-
ed for target protein knockdown by Western blotting and processed 
for subsequent experiments. Alternatively, two independent shRNA 
sequences were used for targeting the 3′ UTR of human SNPH: TRCN 
0000147900 and TRCN 0000128545 (Wistar Molecular Screening 
Shared Resource). An empty pLKO-based lentivirus was used as con-
trol. PC3 cells stably expressing shRNA targeting SNPH were generat-
ed by infection with lentiviral particles, followed by a 2-week selection 
in the presence of puromycin at 2 μg/ml.
According to this model, downregulation of SNPH due to hypoxic 
or oxidative stress (1) turns the rheostat toward greater cell motility 
at the expense of cell proliferation (Figure 9). Fueled by increased 
mitochondrial accumulation at the cortical cytoskeleton (25), the 
resulting heightened cell motility may provide an “escape” mech-
anism for tumor cells to evade an unfavorable ecosystem and col-
onize alternative, distant tissue sites (49). Conversely, sustained 
levels of oxygen and nutrients maintain high SNPH expression in 
mitochondria. This turns the rheostat toward continued tumor cell 
proliferation enabled by low ROS production and efficient oxida-
tive metabolism, while restricting mitochondrial trafficking and 
cell movements (Figure 9).
Although metastatic disease is the primary cause of death for 
cancer patients, there is a paucity of therapeutic targets to inter-
fere with the process(es) of tumor cell dissemination to distant 
organs (50). In line with the renewed emphasis of mitochondria 
in metastasis (19, 21, 29), molecules in the SNPH pathway may 
provide fresh therapeutic opportunities to target adaptive mech-
anisms of cell proliferation-motility in progressive disease. As this 
pathway is selectively exploited in cancer, as opposed to normal 
tissues, modulators of mitochondrial trafficking may constitute a 
favorable strategy and be uniquely suited to disrupt the metabolic 
requirements of metastatic cells (29).
Methods
Antibodies and reagents. A custom rabbit polyclonal antibody against 
human SNPH (aa 207–221) was produced by NEO Group Inc. and 
purified by antigen affinity. The anti-SNPH custom antibody was 
validated in knockdown cells (Supplemental Figure 1, D and E) and 
in cells overexpressing SNPH cDNA (Supplemental Figure 2D) at 
a 1:1,000 dilution. Antibodies to Prx3 (Santa Cruz Biotechnology 
Inc., clone 4G10, catalog sc-59663, diluted 1:3,000), 2-Cys Prx-SO3 
(Thermo Fisher Scientific Inc., clone 10A1, catalog LF-MA0088, 
diluted 1:1,000), FLAG (Sigma-Aldrich, clone M-2, catalog F1804, 
diluted 1:5,000), SDHA (Abcam, clone 2E3GC12FB2AE2, catalog 
14715, diluted 1:5,000), SDHB (Abcam, clone 21A11AE7, catalog 
14714, diluted 1:2,000), oxidative phosphorylation antibody cock-
tail (MitoSciences, Abcam catalog s110411, diluted 1:2,000), citrate 
synthase (CS, clone D7V8B, catalog 14309), SOD2 (clone D3X8F, 
catalog 13141), catalase (clone D4P7B, catalog 12980), Axl (clone 
C89E7, catalog 8661), COX-IV (clone 4D11-B3-E8, catalog 11967), 
Nrf2 (clone D1Z9C, catalog 12721), caveolin 1 (clone D46G3, catalog 
3267), VDAC (catalog 4866), HIF1α (catalog 3716), β-catenin (clone 
D10A8, catalog 8480), Slug (clone C19G7, catalog 9585), ZO1 (clone 
D7D12, catalog 8193), claudin 1 (clone D5H1D, catalog 13255), ZEB1 
(clone D80D3, catalog 3396), vimentin (clone D21H3, catalog 5741) 
(Cell Signaling Technology, all diluted 1:1,000), and β-actin (Sig-
ma-Aldrich, clone AC-15, cat#A5441, diluted 1:100,000) were used 
for Western blotting. Antibodies to paxillin (Upstate Biotechnologies, 
clone 5H11, Millipore catalog 05-417), β-tubulin (Sigma-Aldrich, 
clone AA2, catalog T8328), Tom20 (Santa Cruz Biotechnology Inc., 
clone FL-145, catalog sc11415), and MTC02 (Abcam, clone MTC02, 
catalog 79479) were used for immunofluorescence. DMNQ, FCCP, 
CHX, MT (>98% TLC), and N-acetyl-cysteine (NAC, >99% HPLC) 
were from Sigma-Aldrich. MitoTracker Green, phalloidin Alexa Fluor 
488, CellLight Mito-RFP BacMam 2.0, and secondary antibodies for 
immunofluorescence were from Molecular Probes.
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GATGGGCGGTATC; probe, CAGTGGACTCAGCCCCC. A standard 
synthetic gBlock containing the target amplicons for common SNPH 
(S+L), short SNPH, long SNPH, actin, and GAPDH in tandem (CSLAG) 
was purchased from IDT. The efficiency of amplification (Ex) of the 
3 assays (long, short, and common SNPH) was determined using the 
Ct slope method with 6 concentrations of CSLAG standard covering a 
5-log range, and found to be identical (P > 0.05 for all comparisons). The 
mean and SD were: Ex long = 82.33 ± 8.069; Ex short = 80.90 ± 2.700; 
Ex common = 84.82 ± 7.179. The mean and SD for the correlation coeffi-
cients were: r2 long = 0.9975 ± 0.002500; r2 short = 0.9875 ± 0.01250; r2 
common = 0.9970 ± 0.001000. All r2 values were identical (P > 0.05 for 
all comparisons). Absolute copy number for each transcript was deter-
mined against a standard curve of CSLAG that was run in parallel with 
the cDNA samples. For relative quantitation, the ΔΔCt method was used.
Analysis of SNPH mRNA expression in public databases. The NCBI’s 
Gene Expression Omnibus (GEO) genomics data repository was inter-
rogated for SNPH mRNA expression in primary versus metastatic can-
cer using the GEO Profiles Database (https://www.ncbi.nlm.nih.gov/
geoprofiles/). The “Metastatic prostate cancer” dataset GDS2545 (51, 
52) containing 65 primary prostate and 15 metastases to regional and 
distal lymph nodes was downloaded. The study contained one probe-
set for SNPH (4117_at, GPL8300: [HG_U95Av2] Affymetrix Human 
Genome U95 Version 2 Array). The “Human epidermal growth factor 
receptor 2–positive breast cancer brain metastases” dataset GDS5306 
(53) containing 19 HER+ breast primary non-metastatic and 19 brain 
metastases was downloaded. The study contained 5 probesets for 
SNPH: each probe was searched in the GPL1352: [U133_X3P] Affymet-
rix Human X3P Array and matched to gene bank ID, and the sequence 
was downloaded from the NCBI nucleotide collection and blasted 
against the Human Genomic Plus Transcript (Human G+T). Four 
probes (Hs.323833.1.S1_3p_a_at, Hs.323833.1.S1_3p_at, 215917_3p_at, 
and Hs.323833.1.S1_3p_x_at) were primarily covering a neighbor gene, 
RAD21L1 (NM_001136566.2 at 61% coverage), with a lower coverage 
for SNPH isoforms (38% for either isoform). These 4 probes were dis-
carded from the analyses. Only one probe (ID: g7662081_3p_at) was a 
bona fide probe for SNPH (both isoforms were detected; 100% cover-
age for NM_001318234.1 and 89% coverage for NM_014723.3). Based 
on this probe, primary versus metastatic tumors were compared with a 
2-tailed unpaired Student’s t test using GraphPad Prism 6.0 software.
For the Cancer Cell Line Encyclopedia (CCLE) (54), mRNA 
expression for SNPH was accessed through the cBioPortal for Can-
cer Genomics (http://www.cbioportal.org/) (55, 56) and download-
ed. Individual cancer cell lines were grouped by primary tissue of 
origin according to the CCLE classification and plotted with Graph-
Pad Prism 6.0 software. The TCGA tumor expression data for SNPH 
mRNA (RNA-seq values) were downloaded from the cBioPortal and 
plotted with GraphPad Prism 6.0 software.
For the SNPH versus VHL status analysis, the Kidney Renal Clear 
Cell Carcinoma study (The Cancer Genome Atlas [TCGA; https://can-
cergenome.nih.gov/], Provisional) was downloaded through the cBio-
Portal (55, 56), and the levels of SNPH mRNA were plotted against 
the copy number variation/mutation status of VHL. Outliers were 
tested with Grubbs test and removed from the dataset, and the multi-
ple groups were tested with 1-way ANOVA and Bonferroni’s post-test 
for pairwise comparisons. A correlation between SNPH mRNA levels 
and linear copy number alteration (CNA) for VHL were was examined 
using Spearman’s test using GraphPad Prism 6.0 software.
Protein analysis. For Western blotting, protein lysates were pre-
pared in Triton X-100 lysis buffer (20 mM Tris HCl, pH 7.5, 137 mM 
NaCl, 1% Triton X-100, 10% glycerol) containing EDTA-free Protease 
Inhibitor Cocktail (Sigma-Aldrich) and Phosphatase Inhibitor Cock-
tail PhosSTOP (Roche), sonicated, and precleared by centrifugation 
at 14,000 g for 10 minutes at 4°C. Equal amounts of protein lysates 
were separated by SDS gel electrophoresis, transferred to PVDF mem-
branes, blocked in 5% low-fat milk diluted in TBST buffer (20 mM Tris 
HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20), and further incubated 
with primary antibodies of various specificities diluted 1:1,000 in 5% 
BSA/TBST for 18 hours at 4°C. After washing in TBST, membranes 
were incubated with HRP-conjugated secondary antibodies (1:1,000–
1:5,000 dilution in 5% BSA/TBST) for 1 hour at 22°C and washed with 
TBST, and protein bands were visualized by enhanced chemilumines-
cence. For analysis of protein stability and determination of protein 
half-life, PC3 cells were incubated in the presence of 100 μg/ml of the 
protein synthesis inhibitor CHX, with or without the mitochondrial 
superoxide scavenger MT, and released in complete medium, and ali-
quots of cell lysates collected at increasing time intervals after release 
(2–10 hours) were analyzed by Western blotting.
Mitochondrial isolation. Mitochondrial fractions were prepared 
from PC3 cells using a mitochondrial isolation kit for cultured cells 
(Fisher Scientific). Briefly, PC3 cells were homogenized by 70 strokes 
using a Dounce grinder in isolation buffer A plus protease inhibitor 
cocktail. Cell extracts were collected into equal volumes of isolation 
buffer C with buffer A. Cell debris and nuclei were removed by centrif-
ugation at 700 g for 10 minutes, and mitochondrial fractions were col-
lected by centrifugation at 3,000 g for 25 minutes. For submitochon-
drial fractionation experiments, initial mitochondrial extracts were 
further centrifuged at 12,000 g for 10 minutes in an equal volume of 
isolation buffer C. The resulting samples were further processed by 
sequential centrifugation in fractions containing outer membrane 
(OM), inner membrane (IM), inter-membrane space (IMS), and 
matrix, as described previously (42).
mRNA quantification. Absolute mRNA levels for human SNPH were 
determined by qPCR. Briefly, RNA was extracted with a PureLink RNA 
Mini Kit (Life Technologies) following the in-column DNA digestion 
protocol. For mouse tissues, RNA was extracted from 25 mg of tissue by 
homogeneization in TRI Reagent, followed by purification with a Direct-
zol RNA Mini Kit (Zymo Research). RNA from 8 normal human tissues 
was obtained from BioChain and digested with RNAse-free DNAse I 
(Thermo Scientific). Five micrograms of RNA was reversed transcribed 
using a combination of oligo(dT) and an SNPH-specific reverse primer 
(RNAse-free HPLC purified, CTGGCGGTCACCACAGAC) for 1 hour 
at 53°C using the ThermoScript RT-PCR system (Life Technologies). 
One microliter of cDNA diluted 1:5 was used as template for qPCR 
reactions with TaqMan Gene Expression assays. Pre-designed Taqman 
assays were: mouse Snph (Mm01243855_m1), human long+short (L+S) 
SNPH transcripts (Hs00920132_m1), ACTB (Hs99999903_m1), GAP-
DH (Hs99999905_m1), and eukaryotic 18S rRNA (4352930E).
Custom isoform-specific TaqMan gene expression assays to detect 
Long human SNPH transcript (NM_001318234.1, L-SNPH), or short 
human SNPH transcript (NM_014723, S-SNPH) were used (Figure 
1A). Custom L-SNPH assay primers and probe were: forward, TCAG-
GGTTGTTGAGAGGAGTCA; reverse, CCAGTTGGCCCGTGGTT; 
probe, ATAATACGGGAAGCCCC. Custom S-SNPH assay primers 
and probe were: forward, AGTGGTGCGAGCCG; reverse, GGTGG-
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Mitochondrial respiration complex activity. Extracts from PC3 cells 
stably transduced with pLKO or SNPH-directed shRNA were ana-
lyzed for changes in oxidative phosphorylation complex activity using 
Abcam reagents (for complex I, ab109721; for complex II, ab109908). 
Twenty micrograms of cell lysates was assayed in parallel for citrate 
synthase (CS) activity (ScienCell Research Laboratories). Aliquots 
of lysates with comparable CS activity were applied for quantification 
of mitochondrial oxidative phosphorylation complex activity. Rela-
tive complex activities were calculated by determining the change in 
absorbance over time in the linear range of the measurements.
Cell motility analysis. 2D tumor cell motility experiments were 
carried out as described previously (25). Briefly, 1 × 104 cells under 
the various conditions tested were seeded in 4-well Ph+ chambers 
(Ibidi) in complete medium and allowed to attach overnight. Vid-
eomicroscopy was performed over 10 hours, with a time-lapse inter-
val of 10 minutes. Stacks were imported into ImageJ for analysis. 
Images were aligned according to subpixel intensity registration with 
the StackReg plugin for ImageJ. At least 30 cells were tracked using 
the Manual Tracking plugin for ImageJ, and the tracking data from 
4 independent time-lapse experiments were pooled and exported 
into Chemotaxis and Migration Tool v2.0 (Ibidi) for graphing and 
calculation of mean and SD of speed, accumulated distance, and 
Euclidean distance of movement. For cell migration using a wound 
closure assay, a monolayer of PC3 cells was incubated at 1% O2 for 
24 hours, wounded using a 10-μl pipette tip, immediately returned 
to the hypoxia chamber, and incubated for an additional 20 hours in 
1% O2. Cells were imaged by phase-contrast microscopy,and imag-
es were imported into FIJI software (http://fiji.sc/) and processed to 
measure the area within the wound. The percentage of wound clo-
sure was calculated based on the maximum initial area for each well.
Cell proliferation. For direct cell counting experiments, tumor cells 
were plated in triplicate on 6-MW plates (4 × 104 cells/well) and counted 
at increasing time intervals at 37°C. In parallel, cell viability was mea-
sured by Trypan blue exclusion. Where indicated, ROS scavengers, MT 
(50 μM), or NAC (10 μM), alone or in combination, were added to the 
medium, and fresh medium containing drugs was added every 2 days. 
For colony formation, 200 cells were plated in triplicate onto 6-MW 
plates and allowed to grow for 10–14 days, with fresh medium added 
every 2–3 days. Colonies were stained with 0.5% w/v crystal violet/meth-
anol for 30 minutes at 22°C and quantified by ImageJ. Cell proliferation 
experiments were done by labeling cells in 1:1,000 dilution BrdU (Amer-
sham Pharmacia Biotech) in culture medium for 1 hour and analysis by 
multiparametric flow cytometry with quantitation of BrdU+ cells. Cell 
cycle analysis was carried out in ethanol-fixed cells, stained for 10 min-
utes with 2.5 μl/ml propidium iodide in the presence of ribonuclease A. 
Twenty thousand events were acquired on a FACSCalibur flow cytome-
ter and quantified using CellQuest Pro software (Becton Dickinson).
Animal studies. Groups of 6- to 8-week-old male NOD SCID γ 
(NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) immunocompromised mice 
(Jackson Laboratory) (5 mice per group) were injected s.c. with PC3 
cells stably transfected with pLKO or two independent SNPH-directed 
shRNA sequences (clones 0 and 5), and superficial tumor growth (2 
tumors/mouse) was quantified with a caliper over a 2-week interval. 
At the end of the experiment, animals bearing PC3-pLKO (puromy-
cin-resistant) tumors were euthanized, and the liver and lungs were 
dissected and washed in PBS. Metastatic nodules were excised and cut 
into 1-mm sections, washed in PBS, and plated in RPMI 1640 medi-
Immunofluorescence. Tumor cells were fixed in formalin/PBS (4% 
final concentration) for 15 minutes at 22°C, permeabilized in 0.1% Tri-
ton X-100/PBS for 5 minutes, washed, and incubated in 5% normal 
goat serum (NGS, Vector Laboratories) diluted in 0.3 M glycine/PBS 
for 60 minutes. Primary antibodies against Tom20 (diluted 1:300), 
β-tubulin (diluted 1:200), SNPH (diluted 1:500), and MTC02 (dilut-
ed 1:500) were added in 5% NGS/0.3 M glycine/PBS and incubated 
for 18 hours at 4°C. After 3 washes in PBS, secondary antibodies con-
jugated to Alexa Fluor 488, TRITC, or Alexa Fluor 633 were diluted 
1:500 in 5% NGS/0.3 M glycine/PBS and added to cells for 1 hour at 
22°C. Where indicated, F-actin was stained with phalloidin Alexa Flu-
or 488 (1:200 dilution) for 30 minutes at 22°C. Slides were washed 
and mounted in DAPI-containing ProLong Gold mounting medium 
(Invitrogen). At least 7 random fields were analyzed by fluorescence 
microscopy in a Nikon i80 microscope.
Cortical mitochondria and total mitochondrial mass quantification. 
Mitochondria/F-actin composite images were analyzed in ImageJ 
(NIH), as described previously (25). The F-actin channel was used 
to manually label the cell boundary, and a belt extending from the 
boundary toward the inside of the cell was marked as “cortical mask” 
(see Figure 4B). This cortical mask was subsequently applied to the 
mitochondrial channel to measure intensity at the cortical region, 
which was normalized to total mitochondrial intensity per cell and cell 
area. For quantification of total mitochondrial mass, composite imag-
es were analyzed in ImageJ. The cell border was manually traced on 
the F-actin channel, and this “cell mask” was subsequently applied to 
the mitochondria channel to measure the total mitochondria signal 
per cell. Maximum intensity was monitored to ensure no pixel satu-
ration (e.g., maximum intensity <256 for 8-bit images). Mitochondrial 
mass was normalized to total cell area. A minimum of 30 cells was 
analyzed in each independent experiment to obtain mean values.
Mitochondrial ROS quantification in live cells. Mitochondrial super-
oxide production was analyzed as described previously (25). Briefly, 
1.5 × 104 cells were grown on high-optical-quality 8-well μ-slides (Ibi-
di) and stained with MitoSOX Red mitochondrial superoxide indicator 
(Life Technologies, 5 μM, 10 minutes) in complete medium, followed 
by washes in warm medium. Stained cells were imaged with a 40× 
objective on a Nikon TE300 inverted time-lapse microscope equipped 
with a video system containing an Evolution QEi camera and a time-
lapse video cassette recorder. The atmosphere was equilibrated to 
37°C and 5% CO2 in an incubation chamber. Phase and red fluores-
cence (TRITC filter cube, excitation wavelength 532–554 nm, and 
emission wavelength 570–613 nm) images were captured. For quan-
tification, files were imported into ImageJ, and masks were manually 
created around the periphery of the cell based on the phase image and 
subsequently applied to the TRITC channel to measure intensity. A 
minimum of 100 cells was analyzed in each independent experiment 
to obtain mean values.
Analysis of bioenergetics. Cells were analyzed for ATP generation 
(BioChain catalog Z5030041) or OCR (Enzo Life Sciences catalog 
ENZ-51045-1), according to the manufacturer’s specifications. In 
some experiments, the culture medium was exchanged with dialyzed 
FBS containing growth medium and incubated for 2 hours, followed by 
analysis of lactate production (Abcam, catalog ab65331). For glucose 
consumption, cells were grown for 24 hours at 37°C, and aliquots of 
the culture supernatant were collected and processed using a glucose 
assay kit (eEnzyme).
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um containing puromycin. Tumor cells were allowed to attach to the 
plate overnight, and the next day any residual tissue fragments were 
removed. Four animals were used to generate 4 independent cell lines 
from liver and lung metastatic sites. Parental PC3-pLKO cells were 
used as control for these experiments.
For a syngeneic model of metastasis in vivo, Yale University 
Mouse Melanoma 1.7 (Yumm1.7) 1.7 cells derived from a genetical-
ly engineered mouse model of invasive melanoma with the geno-
type BrafV600E; Cdkn2a–/–;Pten–/– were used (31). Yumm1.7 cells stably 
expressing mCherry were described previously (32). Cells were tran-
siently transfected with empty pCMV6 vector, or cDNAs encoding FL 
short SNPH or ΔMLS SNPH mutant, and selected with G418 at 400 
μg/ml for 15 days. Stably transfected cells (2.5 × 105) were injected into 
the flanks of syngeneic 8-week-old male C57BL/6NCr (NCI Inbred 
mice, Charles River strain code 556). One to 3 weeks later, tumor 
cells disseminated to lungs were identified and quantitated based on 
expression of the mCherry transgene by IHC (see below).
IHC. Lungs were fixed in neutral formalin (Fisher Scientific, SF93-
4) for 36 hours, transferred to 70% ethanol for 3 days, and then paraf-
fin embedded. Five-micrometer sections were stained with a rabbit 
anti-mCherry polyclonal antibody (Novus, NBP2-25157) as follows. 
Slides were warmed at 50°C for 30 minutes; deparaffinized in xylene 
for 20 minutes, then xylene/ethanol 1:1 for 5 minutes; and rehydrat-
ed in alcohol series (100%, 95%, 90%, 70%, 50%, 30% ethanol and 
dH2O, 5 minutes each). Antigen retrieval was done in citrate-based solu-
tion (Vector Laboratories, H-3300) at pH 6.0 in a pressure cooker for 
5 minutes, followed by cooling to room temperature. Next, slides were 
washed once in PBS for 5 minutes and incubated in 3% hydrogen perox-
ide for 20 minutes. Slides were then washed 3 times with PBS (5 minutes 
each) and blocked in 10% normal goat serum/PBS for 1 hour at room 
temperature. Primary antibody was diluted 1:500 in 10% normal goat 
serum/PBS and incubated in a humidified chamber overnight. The next 
day, slides were washed 3 times with PBS for 5 minutes each, incubated 
with anti-rabbit HRP-labeled polymer (Dako, K4002) at room tempera-
ture for 30 minutes, and washed 3 times with PBS for 5 minutes each. 
Slides were developed with a DAB+ substrate chromogen system (Dako, 
K3467) for 30 minutes, rinsed in dH2O, and stained with Mayer’s hema-
toxylin solution (Sigma-Aldrich, MHS16) for 10 seconds. Slides were 
dehydrated in dH2O, 30%, 50%, 70%, 90%, 95%, and 100% ethanol 
(5 minutes each); immersed in xylene for 15 minutes; and mounted with 
Permount mounting medium (Fisher Scientific, SP15-100).
Quantification of disseminated tumor cells to the lungs. Five lungs 
per group were stained for mCherry as described above and scanned 
for the presence of mCherry+ cells in a Nikon i80 upright microscope. 
Each mCherry+ cell was photographed at 40× magnification and 
manually counted using ImageJ software. For each animal, the aver-
age number of mCherry+ cells per lung was calculated and presented. 
ANOVA with Bonferroni’s post-test was used to compare the means 
between the groups and derived pairwise comparison P values.
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